Connect with us

Markets & Industry

What to expect at PSYCH Symposium 2023

Join renowned thought leaders, experts and policymakers at the intersection of psychedelics and healthcare.



Image: The British Museum, Erin Doering

PSYCH Symposium: London 2023 is returning on 6 July at the iconic British Museum to explore the latest challenges and opportunities in the field of psychedelic healthcare. 

There is currently a desperate need for innovative treatments for mental health care, and increasing clinical research is showing that psychedelic medicines hold promise in this area. 

At PSYCH Symposium: London 2023, experts in the field of healthcare, pharma and life sciences will explore the groundbreaking potential of these medicines and discuss cutting-edge psychedelic research that is pushing the boundaries of mental health and addiction care.

See also  Psychedelics as Medicine Report projects industry to reach $3bn by 2026

The inaugural Symposium will also be looking at global and European policy developments, funding challenges and patient access. 

PSYCH Symposium 2023 speakers

Renowned experts and thought leaders from the world of psychedelic research at PSYCH Symposium 2023 include:

  • Professor Robin Carhart-Harris: Head Of The Centre For Psychedelic Research, Imperial College London
  • Professor Celia Morgan: Head Of Ketamine Assisted Psychotherapy For Addiction, Awakn Life Sciences
  • Christian Angermayer: Founder, Apeiron Investment Group
  • Mikuláš Peksa: MEP, European Parliament
  • Dr David Erritzoe: Clinical Senior Lecturer & Consultant Psychiatrist, Imperial College London
  • Tadeusz Hawrot: Founder And Executive Director, PAREA
  • Charlotte Nichols: Labour, Member Of UK Parliament
  • Amir Inamdar: Chief Medical Officer, Cybin Inc
  • George Mcbride: Chief Commercial Officer, Clerkenwell Health

Amongst many more. 

Exploring frontiers in psychedelic healthcare

PSYCH Symposium 2023 will be exploring the intersection of healthcare, policy and psychedelics, giving audiences the opportunity to deepen their understanding of psychedelic research and its current applications. 

Key topics include:

Funding and finance

Panels and fireside chats will explore the current challenges in psychedelic finance and funding, looking at what opportunities remain for investment alongside the consolidation of the market.

Gaming and gambling addictions

This panel with Professor Celia Morgan will look at how psychedelics are revolutionising addiction care, with a specific focus on ketamine-assisted psychotherapy for gaming and gambling addictions. 

Access to psychedelic therapy

There has been a sharp rise in clinical research showing that psychedelics could be radical new treatments for a variety of health issues, but why is mainstream adoption taking so long? 

This panel will explore the unique hurdles facing researchers and companies alike, the reality of this new market, why optimism should be counterbalanced with caution and when we might see meaningful progress toward accessing these therapies.

Future of psychedelic care in Europe

With European politicians now taking notice of psychedelic research, how could the EU take a central role in driving psychedelic healthcare to become a reality across Europe? 

This panel of changemakers and MEPs will discuss how far the needle has moved and what action is needed to bring about an evolution in approach.

Neuroimaging and psychedelics

This panel will uncover the key neuroimaging findings related to psychedelics, as well as explore how these technologies can support and accelerate our knowledge of psychedelic brain mechanisms and the clinical development of associated therapies.

Who will adopt first – public health or big pharma? 

Exploring the current barriers to state-funded psychedelic research, leading experts in the field will discuss the challenges around public healthcare getting involved.

Facilitators and therapists 

With increasing psychedelic clinical trials and an increasing number of countries and US states, such as Oregon and Australia, adopting regulations allowing for access to psychedelic therapies – the need for trained facilitators and therapists that can provide these services is vital. However, currently, there are very limited therapists trained in this area. 

This panel will feature Nadav Modlin of King’s College London, Angela Allbee from Oregon’s Psilocybin Services and more panellists, yet to be announced.

The panellists will be drawing on the recent developments in Oregon to discuss the urgency of companies needing to train therapists now before this becomes a roadblock in the future, and how crucial trained therapists will be in ensuring the development of psychedelic therapies.

These panels, alongside keynote presentations, fireside sessions, expert interviews and networking opportunities, will give audience participants the chance to discover the current state of psychedelic healthcare, policy and industry and learn about the latest findings at the frontier of psychedelic research.

PSYCH Symposium: London 2023 – which is sponsored by Cybin Inc,. Clerkenwell Health and Negev Capital – will be taking place at the British Museum, London, on Thursday, 6 July 2023.

For further information on speakers, panel discussions, sponsorship opportunities or the latest ticket offers, along with future panel and speaker announcements, visit, or sign up for the PSYCH Symposium newsletter at here

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Markets & Industry

Psychedelic therapy programmes launch to address heartbreak, burnout and more



Psychedelic therapy programmes launch to address heartbreak, burnout and more

Mindbloom has launched its new Mastermind Series of psychedelic programmes for overcoming heartbreak, burnout and other unique mental health challenges. 

Led by and developed with leading experts in the field, each programme combines specialised teachings with ketamine therapy.

All programmes will include six ketamine therapy sessions focusing on a specific mental health issue, expert-led audio, video, and written content for preparation, treatment, and integration, practical tools such as meditation, one-on-one coaching and group integration sessions.

See also  Psychedelics for frontline workers, palliative care and eating disorders

The first programme in the Series is ‘Recovering from Rejection and Failure’, led by Dr Guy Winch who is a leading authority on emotional health, and a best-selling author and TED speaker whose talks have received over 30 million views.

Winch’s programme focuses on healing and preventing emotional injuries that people suffer in their personal, professional and romantic lives.

Mindbloom CEO and Founder Dylan Beynon stated: “More than 100 studies and 20 plus years of clinical use show that ketamine therapy may be the most transformational mental health treatment available today.

“In the face of epidemics of mental illness, addiction, and loneliness, we’re thrilled to offer our clients access to top experts across a range of issues – and to pair their expertise with our best-in-class ketamine therapy honed over hundreds of thousands of treatment sessions.”

“Emotional wounds like rejection and failure can be even more devastating than physical wounds, yet we don’t give them the same time and attention,” added Dr Winch.

“I’m thrilled to combine my techniques for emotional first aid with ketamine therapy, which has been shown to increase neuroplasticity and help build emotional resilience.”

Additional Mastermind programmes will be released in the coming months, including: Getting Unstuck, by Dr Elizabeth Lombardo; Beating Burnout, by Dr Shauna Shapiro; and Coping with Cravings, by Dr Jud Brewer

“Americans are struggling with heartbreak, burnout, and other challenges every day, and they’re looking for new tools to address them,” said Mindbloom’s Medical Director Dr Leonardo Vando.

“I’m grateful to these experts for providing Mindbloom’s clients with the unique practices and insights they’ve cultivated during their distinguished careers, to help them overcome the biggest obstacles in their lives.”

Continue Reading

Markets & Industry

Mychedelica launches to revolutionise psychedelic medicine



Mychedelica launches to revolutionise psychedelic medicine

A new company specialising in psychedelic medicine – mychedelica – is offering a comprehensive suite of services to support the advancement of this transformative field. 

With a team of experienced medical writers and research support specialists, mychedelica is committed to providing the highest quality services to researchers, clinicians, and pharmaceutical companies working in the psychedelic medicine space.

Psychedelic medicine is rapidly gaining recognition for its potential to treat a wide range of mental health conditions, including depression, anxiety, addiction, and post-traumatic stress disorder (PTSD). However, the field is still in its early stages of development, and there is a critical need for high-quality medical writing and research support services to facilitate its progress.

CEO of mychedelica, Bilal Bham, commented: “We are thrilled to launch mychedelica and contribute to the advancement of psychedelic medicine.

“Our team of experienced professionals is dedicated to providing the highest quality services to researchers, clinicians, and pharmaceutical companies working in this groundbreaking field.”

mychedelica provides a comprehensive range of services, including:

Medical writing: Experienced medical writers will craft clinical trial protocols, regulatory submissions, and peer-reviewed publications, ensuring that research findings are communicated clearly and effectively.

Funding research support: Experts in grant writing and fundraising strategies will assist researchers in securing funding for their psychedelic medicine studies.

Regulatory consulting: mychedelica’s team of regulatory experts will navigate the complex regulatory landscape surrounding psychedelic medicine, ensuring that clinical trials and products comply with all applicable laws and regulations.

With its commitment to quality and innovation, mychedelica is poised to play a pivotal role in shaping the future of psychedelic medicine. The company’s services will empower researchers to conduct rigorous clinical trials, clinicians to provide effective treatments, and pharmaceutical companies to develop safe and effective psychedelic medicines.

Continue Reading

Markets & Industry

Short Wave Pharma: innovating eating disorder care with psychedelics



Short Wave Pharma: innovating eating disorder care psychedelics

Psychedelic Health speaks to Short Wave Pharma CEO Rivki Stern about the company’s plans to innovate eating disorder care through psychedelics and its recent acquisition by Psych Capital.

Short Wave Pharma was recently acquired by global investment firm Psych Capital. The companies are on a mission to transform mental health care, focusing on innovative approaches and treatments, including psychedelics, which are increasingly gaining acceptability as clinical research results accumulate.

Short Wave Pharma’s clinical programmes are particularly focused on Anorexia nervosa – a complex mental health condition with one of the highest fatality rates. Despite the condition being associated with high rates of suicide, it is a hugely underserved area of mental health, with no FDA-approved pharmacological drug, and a high rate of chronicity. 

See also  Psych Capital completes acquisition of Short Wave Pharma

The company has developed a novel delivery method and drug combination specifically designed to address the requirements of this vulnerable population. Short Wave focuses on methods of delivery that will be effective for Anorexia, which is a metabolic disease as well as a mental health condition. Its unique buccal film delivery method is intended to affect the brain while bypassing the liver and gut degradation through mucoadhesive absorption.

“Our goal is to alleviate, solve, and treat mental health conditions. It’s a dire need in our global society, and it’s constantly on the rise,” commented Stern. “Eating disorders are a very good example of that and we have seen a very alarming growth since COVID. 

“What drew our attention to psychedelics is that they have the potential to address very complex mental health diseases and have been designated by FDA as breakthrough medicine for life-threatening conditions.

“Because there are no current solutions, we must harness very innovative approaches and potential solutions. That’s why we started working with psychedelics which may be difficult because they are not regulated, but we don’t shy away from challenges.”

The company’s drug is based on psilocybin and another API which together utilise an expanded mechanism of action and a therapeutic effect superior to psilocybin alone, impacting more than one group of receptors in the brain. 

The delivery method is sensitive to the patients’ needs – who may not want to swallow or be injected – and is known for its high bioavailability. 

“By mucosal absorption, we are speeding the onset of the medicine and amplifying the impact which will help tackle the patients’ metabolic challenges and improve acceptance,” says Stern. 

The drug product and delivery method are currently in preparation for Phase 1 clinical studies, and in its current preclinical studies, the company is validating its delivery and expanded mechanisms of action. So far, initial safety results are positive, with a further, more in-depth toxicity study taking place. 

Psych Capital – which is a public investment and awareness platform for mental health, and has a portfolio of innovative companies – has supported Short Wave Pharma’s IP-driven approach to eating disorder care through its recent acquisition of the company.

Short Wave and Psych Capital say they are aligned in their missions to innovate mental healthcare and deliver transformative care in areas of high unmet need.

Stern commented: “We all share a passion for innovation and together have decades of experience in evaluating investments as well as scaling up R&D projects and start-ups in life sciences. 

“We have a shared commitment to alleviate the suffering from mental health. Every one of us has experienced the frustration and challenges of dealing with mental health issues.

“Together, we’re going to put this commitment into action, by bringing forth innovative solutions and developments and getting them through the first stages of development, from discovery through to early phases of clinical study. 

“With psychedelics components, this is extra challenging because of their status as scheduled drugs within a still evolving regulatory framework, which adds uncertainty to the drug development process. 

“Short Wave Pharma has operational expertise in early-stage drug development which will bring extra value to the group’s projects as they develop through our funnel and grow into promising candidates for mental healthcare.  

“We want to identify the gems, guide them through clinical development, and create the right network to attract the right partners for further development and commercialisation.”

Short Wave Pharma is planning to enter its treatment into clinical studies in 2024.

Continue Reading